drugset / Trial / NCT05125068
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 2a, multicenter, open-label study designed to evaluate the safety and efficacy of AT-1501 in patients with biopsy proven IgAN and at least 0.75 g/24 hours of protein in their urine at the time of screening.
Timeline
- Start
- 2022-03-21
- Primary completion
- 2023-07-31
- Completion
- 2023-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tegoprubart | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Tegoprubart | Monoclonal antibody | 10 mg/kg | Intravenous |